

Nelson, Bettie L

From: Michael Szwanek (402)437-4880 [Michael.Szwanek@mdsps.com]
Sent: Wednesday, October 16, 2002 1:37 PM
To: Hans-Juergen.Roethig@pmusa.com
Cc: bettie.l.nelson@pmusa.com; Megan McCrory; Robert Earl; Kimberly Prchal
Subject: Amendment Two for JLI

Sensitivity: Confidential



28030_AMEND
VO_11OCT02_Phillip

Hans,

Attached is Amendment Two for EHCJLI/01/02 allowing for repeat NNAL/NNAL-glucuronide and additional biomarker analysis (1,3-Butadiene metabolites, S-PMA, 1-OHP) on reserve urine.

IRB approval was granted at the Oct 15, 2002 IRB meeting.

Thanks,

Michael F. Szwanek, Pharm D., MBA
Section Head, Protocol Development and ICFs
MDS Pharma Services - Lincoln, NE
michael.szwanek@mdsps.com
(402) 437-4880